Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 5/20 | 0.49 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.49 |
| ▸ | ITK | Q08881 | 11/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | DDO | Q99489 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13515273 | 0.82 | CDK5 (0.49) | CDK5CDK5R1ITKDAODDO | |
| SCHEMBL2933463 | 0.80 | RAB9A (0.51) | CDK5CDK5R1ITKMAPTAURKA | |
| SCHEMBL2930773 | 0.73 | CDK5 (0.49) | CDK5CDK5R1ITKDAOMAPT | |
| SCHEMBL6491212 | 0.72 | ITK (0.54) | ITKDAODDOMAPTRXFP1 | |
| SCHEMBL2789205 | 0.70 | CYP19A1 (0.68) | CDK5CDK5R1ITKMAPT | |
| SCHEMBL31626907 | 0.70 | KDM4E (0.39) | CDK5CDK5R1ITK | |
| SCHEMBL4901225 | 0.70 | CYP11B2 (0.49) | MAPT | |
| SCHEMBL13183689 | 0.70 | RAB9A (0.54) | ITKDAODDOMAPTRXFP1 | |
| SCHEMBL8288035 | 0.69 | DAO (0.52) | ITKDAODDOMAPTRXFP1 | |
| SCHEMBL1606038 | 0.69 | CDK5 (0.49) | CDK5CDK5R1DAOMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| CN-101472912-A | Pyridine and pyrazine derivatives as MNK kinase inhibitors | BIOVITRUM AB PUBL (SE) | 2009-07-01 | — | — | CN | disclosed |
| EP-2044051-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (publ) (SE) | 2009-04-08 | — | — | EP | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| WO-2007147874-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (PUBL) (SE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039450-A1 | Compounds | NEK2, CSNK2A3, CSNK2A1 | CDK5 240/4885CDK5R1 205/4885ITK 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.